romosozumab或denosumab治疗6个月对类风湿关节炎合并严重骨质疏松患者骨密度和疾病活动度的影响:一项开放标签、随机、试点研究

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM Osteoporosis and Sarcopenia Pub Date : 2021-09-01 DOI:10.1016/j.afos.2021.08.001
Takeshi Mochizuki , Koichiro Yano , Katsunori Ikari , Ken Okazaki
{"title":"romosozumab或denosumab治疗6个月对类风湿关节炎合并严重骨质疏松患者骨密度和疾病活动度的影响:一项开放标签、随机、试点研究","authors":"Takeshi Mochizuki ,&nbsp;Koichiro Yano ,&nbsp;Katsunori Ikari ,&nbsp;Ken Okazaki","doi":"10.1016/j.afos.2021.08.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>To investigate effects of romosozumab treatment on disease activity and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) and severe osteoporosis in comparison with effects of denosumab treatment.</p></div><div><h3>Methods</h3><p>A total of 50 women were enrolled in this study. The subjects were randomized equally into 2 groups: the romosozumab group or the denosumab group. Disease activity score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) and BMD at lumbar spine were evaluated.</p></div><div><h3>Results</h3><p>The percent changes (Δ) in the BMD values at 3 and 6 months for the lumbar spine were as follows: romosozumab; 4.9% and 5.2%, denosumab: 2.3% and 3.2%. The ΔBMD for the lumbar spine at 3 months was significantly higher in the romosozumab group than in the denosumab group (P = 0.044). The DAS28-ESR at baseline, 3 and 6 months in the romosozumab group were 2.88, 2.60 (P = 0.427) and 2.58 (P = 0.588), respectively. The change from baseline in DAS28-ESR did not differ significantly between these 2 groups at any time point.</p></div><div><h3>Conclusions</h3><p>The present study revealed that romosozumab treatment is more effective than denosumab treatment in increasing BMD of the lumbar spine at 3 months. Furthermore, the present study suggested that romosozumab treatment has no effects on the disease activity of RA in patients with RA and severe osteoporosis for 6 months.</p></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.afos.2021.08.001","citationCount":"6","resultStr":"{\"title\":\"Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study\",\"authors\":\"Takeshi Mochizuki ,&nbsp;Koichiro Yano ,&nbsp;Katsunori Ikari ,&nbsp;Ken Okazaki\",\"doi\":\"10.1016/j.afos.2021.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>To investigate effects of romosozumab treatment on disease activity and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) and severe osteoporosis in comparison with effects of denosumab treatment.</p></div><div><h3>Methods</h3><p>A total of 50 women were enrolled in this study. The subjects were randomized equally into 2 groups: the romosozumab group or the denosumab group. Disease activity score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) and BMD at lumbar spine were evaluated.</p></div><div><h3>Results</h3><p>The percent changes (Δ) in the BMD values at 3 and 6 months for the lumbar spine were as follows: romosozumab; 4.9% and 5.2%, denosumab: 2.3% and 3.2%. The ΔBMD for the lumbar spine at 3 months was significantly higher in the romosozumab group than in the denosumab group (P = 0.044). The DAS28-ESR at baseline, 3 and 6 months in the romosozumab group were 2.88, 2.60 (P = 0.427) and 2.58 (P = 0.588), respectively. The change from baseline in DAS28-ESR did not differ significantly between these 2 groups at any time point.</p></div><div><h3>Conclusions</h3><p>The present study revealed that romosozumab treatment is more effective than denosumab treatment in increasing BMD of the lumbar spine at 3 months. Furthermore, the present study suggested that romosozumab treatment has no effects on the disease activity of RA in patients with RA and severe osteoporosis for 6 months.</p></div>\",\"PeriodicalId\":19701,\"journal\":{\"name\":\"Osteoporosis and Sarcopenia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2021-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.afos.2021.08.001\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Osteoporosis and Sarcopenia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405525521000583\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoporosis and Sarcopenia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405525521000583","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 6

摘要

目的探讨romosozumab治疗对类风湿关节炎(RA)和严重骨质疏松症患者疾病活动性和骨密度(BMD)的影响,并与denosumab治疗进行比较。方法本研究共纳入50名妇女。受试者被随机分为2组:romosozumab组或denosumab组。评估28个关节疾病活动度评分(DAS28)、红细胞沉降率(ESR)和腰椎骨密度。结果3个月和6个月腰椎骨密度值变化百分比(Δ)如下:romosozumab;4.9%和5.2%,denosumab: 2.3%和3.2%。3个月时,romosozumab组腰椎的ΔBMD明显高于denosumab组(P = 0.044)。romosozumab组基线、3和6个月DAS28-ESR分别为2.88、2.60 (P = 0.427)和2.58 (P = 0.588)。两组在任何时间点DAS28-ESR的基线变化无显著差异。结论本研究显示,在增加3个月腰椎骨密度方面,罗莫索单抗治疗比地诺单抗治疗更有效。此外,本研究提示romosozumab治疗对RA合并严重骨质疏松患者6个月的RA疾病活动度无影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study

Objectives

To investigate effects of romosozumab treatment on disease activity and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) and severe osteoporosis in comparison with effects of denosumab treatment.

Methods

A total of 50 women were enrolled in this study. The subjects were randomized equally into 2 groups: the romosozumab group or the denosumab group. Disease activity score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) and BMD at lumbar spine were evaluated.

Results

The percent changes (Δ) in the BMD values at 3 and 6 months for the lumbar spine were as follows: romosozumab; 4.9% and 5.2%, denosumab: 2.3% and 3.2%. The ΔBMD for the lumbar spine at 3 months was significantly higher in the romosozumab group than in the denosumab group (P = 0.044). The DAS28-ESR at baseline, 3 and 6 months in the romosozumab group were 2.88, 2.60 (P = 0.427) and 2.58 (P = 0.588), respectively. The change from baseline in DAS28-ESR did not differ significantly between these 2 groups at any time point.

Conclusions

The present study revealed that romosozumab treatment is more effective than denosumab treatment in increasing BMD of the lumbar spine at 3 months. Furthermore, the present study suggested that romosozumab treatment has no effects on the disease activity of RA in patients with RA and severe osteoporosis for 6 months.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Osteoporosis and Sarcopenia
Osteoporosis and Sarcopenia Orthopedics, Sports Medicine and Rehabilitation, Endocrinology, Diabetes and Metabolism, Obstetrics, Gynecology and Women's Health, Geriatrics and Gerontology
自引率
5.00%
发文量
23
审稿时长
66 days
期刊最新文献
Does intradiscal steroid injection accelerate the histological degeneration of the human disc? Surgery for spinal deformity with osteoporosis: Achieving successful fusion Verification of grip strength as an evaluation tool for locomotive syndrome in rheumatoid arthritis Effects of whole-body vibration on bone properties in type 2 diabetes model rats Choice of cemented or uncemented stems for displaced femoral neck fractures
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1